Antiagregación y anticoagulación en síndromes coronarios agudos: niveles de evidencia
Keywords: 
Acute coronary syndrome
Antiplatelets
Anticoagulants
Low-molecular weight heparins
Issue Date: 
2007
Publisher: 
Ediciones Universidad de Navarra
ISSN: 
0556-6177
Citation: 
Paramo JA, Garcia R, Rodriguez P, de Gaona ER. Antiagregación y anticoagulación en síndromes coronarios agudos: niveles de evidencia. Rev Med Univ Navarra 2007 Jan-Mar;51(1):23-27.
Abstract
Management of acute coronary syndromes (ACS) has moved rapidly in parallel with our understanding of the pathophysiological basis of the disease. In the eighties, the demonstration of the pivotal role of coronary thrombosis in the etiology of a ACS led to administration of aspirin and unfractionated heparin. In recent years, new medical and invasive therapies have been developed: anti-platelets (thienopyridines and glycoprotein Ilb/IlIa inhibitors), antithrombins (low molecularweight heparins) and most recently, factor Xa inhibitors (pentasaccharides). As new treatments are rapidly added, clinicians are constantly challenged to incorporate new information and guidelines into their practices in a timely fashion.

Files in This Item:
File: 
RevMedUnivNavarra2007_5123.pdf
Description: 
Size: 
36 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.